Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fujifilm/MediVector antiviral favipiravir advances in Ebola

This article was originally published in Scrip

Executive Summary

Favipiravir (T-705), an antiviral drug that initially was developed by Fujifilm and its US subsidiary MediVector to fight seasonal influenza, is advancing into clinical testing in Guinea as a treatment for Ebola – trials whose preliminary results could be available by as early as year end, a company official said on 11 November.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts